W. Rathmell
Last active: 4/27/2021

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.

McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, Sznol M, Hainsworth J, Rathmell WK, Stadler WM, Hutson T, Gore ME, Ravaud A, Bracarda S, Suárez C, Danielli R, Gruenwald V, Choueiri TK, Nickles D, Jhunjhunwala S, Piault-Louis E, Thobhani A, Qiu J, Chen DS, Hegde PS, Schiff C, Fine GD, Powles T
Nat Med. 2018 24 (6): 749-757

PMID: 29867230 · PMCID: PMC6721896 · DOI:10.1038/s41591-018-0053-3

MeSH Terms (19)

Adult Aged Aged, 80 and over Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols Bevacizumab Carcinoma, Renal Cell Female Gene Expression Profiling Gene Expression Regulation, Neoplastic Humans Kaplan-Meier Estimate Kidney Neoplasms Male Middle Aged Mutation Sunitinib Treatment Outcome

Connections (1)

This publication is referenced by other Labnodes entities:

Links